TY - JOUR
T1 - Long-term quality of life and exocrine and endocrine insufficiency after pancreatic surgery
T2 - a multicenter, cross-sectional study
AU - Latenstein, Anouk E.J.
AU - Blonk, Lotte
AU - Tjahjadi, Nic S.
AU - de Jong, Nenke
AU - Busch, Olivier R.
AU - de Hingh, Ignace H.J.T.
AU - van Hooft, Jeanin E.
AU - Liem, Mike S.L.
AU - Molenaar, Isaaq Q.
AU - van Santvoort, Hjalmar C.
AU - de van der Schueren, Marian A.E.
AU - DeVries, J. Hans
AU - Kazemier, Geert
AU - Besselink, Marc G.
N1 - Funding Information:
AL has received research funding from Mylan and Allergan.
Funding Information:
The Dutch Pancreatic Cancer Project was supported by the Dutch Cancer Society (KWF Kankerbestrijding; grant no. UVA2013-5842 ).
Publisher Copyright:
© 2021
PY - 2021/11
Y1 - 2021/11
N2 - Background: Data regarding long-term quality of life and exocrine and endocrine insufficiency after pancreatic surgery for premalignant and benign (non-pancreatitis) disease are lacking. Methods: This cross-sectional study included patients ≥3 years after pancreatoduodenectomy or left pancreatectomy in six Dutch centers (2006–2016). Outcomes were measured with the EQ-5D-5L, the EORTC QLQ-C30, an exocrine and endocrine pancreatic insufficiency questionnaire, and PAID20. Results: Questionnaires were completed by 153/183 patients (response rate 84%, median follow-up 6.3 years). Surgery related complaints were reported by 72/153 patients (47%) and 13 patients (8.4%) would not undergo this procedure again. The VAS (EQ-5D-5L) was 76 ± 17 versus 82 ± 0.4 in the general population (p < 0.001). The mean global health status (QLQ-C30) was 78 ± 17 versus 78 ± 17, p = 1.000. Fatigue, insomnia, and diarrhea were clinically relevantly worse in patients. Exocrine pancreatic insufficiency was reported by 62 patients (41%) with relieve of symptoms by enzyme supplementation in 48%. New-onset diabetes mellitus was present in 22 patients (14%). The median PAID20 score was 6.9/20 (IQR 2.5–17.8). Conclusion: Although generic quality of life after pancreatic resection for pre-malignant and benign disease was similar to the general population and diabetes-related distress was low, almost half suffered from a range of symptoms highlighting the need for long-term counseling.
AB - Background: Data regarding long-term quality of life and exocrine and endocrine insufficiency after pancreatic surgery for premalignant and benign (non-pancreatitis) disease are lacking. Methods: This cross-sectional study included patients ≥3 years after pancreatoduodenectomy or left pancreatectomy in six Dutch centers (2006–2016). Outcomes were measured with the EQ-5D-5L, the EORTC QLQ-C30, an exocrine and endocrine pancreatic insufficiency questionnaire, and PAID20. Results: Questionnaires were completed by 153/183 patients (response rate 84%, median follow-up 6.3 years). Surgery related complaints were reported by 72/153 patients (47%) and 13 patients (8.4%) would not undergo this procedure again. The VAS (EQ-5D-5L) was 76 ± 17 versus 82 ± 0.4 in the general population (p < 0.001). The mean global health status (QLQ-C30) was 78 ± 17 versus 78 ± 17, p = 1.000. Fatigue, insomnia, and diarrhea were clinically relevantly worse in patients. Exocrine pancreatic insufficiency was reported by 62 patients (41%) with relieve of symptoms by enzyme supplementation in 48%. New-onset diabetes mellitus was present in 22 patients (14%). The median PAID20 score was 6.9/20 (IQR 2.5–17.8). Conclusion: Although generic quality of life after pancreatic resection for pre-malignant and benign disease was similar to the general population and diabetes-related distress was low, almost half suffered from a range of symptoms highlighting the need for long-term counseling.
UR - https://www.scopus.com/pages/publications/85106231311
U2 - 10.1016/j.hpb.2021.04.012
DO - 10.1016/j.hpb.2021.04.012
M3 - Article
AN - SCOPUS:85106231311
SN - 1365-182X
VL - 23
SP - 1722
EP - 1731
JO - HPB
JF - HPB
IS - 11
ER -